Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders
Clinical trial NCT02392559 · COMPLETED
Trial details
- NCT number
- NCT02392559
- Sponsor
- Amgen
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-03-24
- Primary completion
- 2019-11-25
- Enrollment
- 158
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.